These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11927124)

  • 1. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin.
    Mayr AJ; Dünser M; Jochberger S; Fries D; Klingler A; Joannidis M; Hasibeder W; Schobersberger W
    Thromb Res; 2002 Feb; 105(3):201-4. PubMed ID: 11927124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.
    Jochberger S; Mayr V; Luckner G; Fries DR; Mayr AJ; Friesenecker BE; Lorenz I; Hasibeder WR; Ulmer H; Schobersberger W; Dünser MW
    Crit Care; 2005 Oct; 9(5):R541-8. PubMed ID: 16277716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifactor Xa levels in critically ill Korean patients receiving enoxaparin for thromboprophylaxis: a prospective observational study.
    Lim SY; Jeon K; Kim HJ; Kim SM; Song J; Ha JM; Um SW; Koh WJ; Chung MP; Kim H; Kwon OJ; Suh GY
    J Korean Med Sci; 2013 Mar; 28(3):466-71. PubMed ID: 23487580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enoxaparin dose adjustment is associated with low incidence of venous thromboembolic events in acute burn patients.
    Lin H; Faraklas I; Saffle J; Cochran A
    J Trauma; 2011 Dec; 71(6):1557-61. PubMed ID: 22027887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Evaluation of Weight-Based Prophylactic Enoxaparin Dosing in Critically Ill Trauma Patients: Adequacy of AntiXa Levels Is Improved.
    Nunez JM; Becher RD; Rebo GJ; Farrah JP; Borgerding EM; Stirparo JJ; Lauer C; Kilgo P; Miller PR
    Am Surg; 2015 Jun; 81(6):605-9. PubMed ID: 26031274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enoxaparin thromboprophylaxis in gastric bypass patients: extended duration, dose stratification, and antifactor Xa activity.
    Borkgren-Okonek MJ; Hart RW; Pantano JE; Rantis PC; Guske PJ; Kane JM; Gordon N; Sambol NC
    Surg Obes Relat Dis; 2008; 4(5):625-31. PubMed ID: 18261965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety.
    Lachish T; Rudensky B; Slotki I; Zevin S
    Pharmacotherapy; 2007 Oct; 27(10):1347-52. PubMed ID: 17896889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
    Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
    Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-Factor Xa measurements in acute care surgery patients to examine enoxaparin dose.
    Wall V; Fleming KI; Tonna JE; Nunez J; Lonardo N; Shipley RW; Nirula R; Pannucci CJ
    Am J Surg; 2018 Aug; 216(2):222-229. PubMed ID: 28736059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients.
    Van PY; Cho SD; Underwood SJ; Morris MS; Watters JM; Schreiber MA
    J Trauma; 2009 Jun; 66(6):1509-15; discussion 1515-7. PubMed ID: 19509608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enoxaparin 40 mg per Day Is Inadequate for Venous Thromboembolism Prophylaxis After Thoracic Surgical Procedure.
    Pannucci CJ; Fleming KI; Holoyda K; Moulton L; Prazak AM; Varghese TK
    Ann Thorac Surg; 2018 Aug; 106(2):404-411. PubMed ID: 29626461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-therapeutic anti-FXa levels are common among medical ward patients treated with enoxaparin.
    Saliba W; Nitzan O; Rock W; Ron G; Zalman L; Goldstein L; Lavi I; Elias M
    Ann Hematol; 2011 Nov; 90(11):1345-51. PubMed ID: 21409381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
    Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enoxaparin and antifactor Xa levels in acute burn patients.
    Lin H; Faraklas I; Cochran A; Saffle J
    J Burn Care Res; 2011; 32(1):1-5. PubMed ID: 21124231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Factor Xa Levels in Low-weight Surgical Patients Receiving Enoxaparin for Venous Thromboembolism Prophylaxis: A Prospective Cohort Study.
    Hakeam HA; Al Duhailib Z; Alsemari M; Alwaibah RM; Al Shannan MF; Shalhoub M
    Clin Appl Thromb Hemost; 2020; 26():1076029620931194. PubMed ID: 32559127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients.
    Lee YR; Vega JA; Duong HN; Ballew A
    Pharmacotherapy; 2015 Nov; 35(11):1007-15. PubMed ID: 26598093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment.
    Sanderink GJ; Guimart CG; Ozoux ML; Jariwala NU; Shukla UA; Boutouyrie BX
    Thromb Res; 2002 Feb; 105(3):225-31. PubMed ID: 11927128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C; Omran H; Tripp C; Poetzsch B
    Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5?
    Yildirim T; Kocak T; Buyukasik Y; Yilmaz R; Altun B; Erdem Y; Arici M
    Blood Coagul Fibrinolysis; 2012 Dec; 23(8):700-4. PubMed ID: 23135378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.